Guselkumab治疗TNF抑制剂应答不佳的活动性银屑病关节炎24周III期结果
SOLSTICE研究纳入对一种既往TNF抑制剂应答不佳的活动性银屑病关节炎成人患者451例,随机接受Guselkumab每4周、每8周或安慰剂治疗。24周时两种Guselkumab方案的ACR20、ACR50、ACR70、IGA 0/1、PASI90及MDA应答率均显著高于安慰剂(所有P<0.001)。安全性与已知特征一致。
要点
- 对一种TNF抑制剂应答不佳的活动性PsA患者,Guselkumab 24周疗效显著优于安慰剂。
- 两种给药方案(Q4W与Q8W)疗效相近,ACR20分别达58.6%和62.2%。
- 安全性事件发生率与安慰剂相近,总体与已知安全性特征一致。
核心结论
- 对一种既往TNF抑制剂应答不佳的活动性银屑病关节炎患者,Guselkumab在第24周显示出显著优于安慰剂的疗效。
研究设计与样本
- SOLSTICE为IIIb期随机、多中心、双盲、安慰剂对照研究。
- 纳入活动性PsA成人患者(肿胀关节≥3个、压痛关节≥3个、C反应蛋白≥0.3 mg/dL)且对一种既往TNF抑制剂应答不佳。
- 随机分为Guselkumab 100 mg每4周、Guselkumab 100 mg第0和4周后每8周、或安慰剂(第24周转用Guselkumab每4周)组。
- 分析纳入451例随机参与者(每4周组n=150;每8周组n=151;安慰剂组n=150)。
主要发现
- 第24周,Guselkumab每4周/每8周组与安慰剂组分别有58.6%/62.2% vs 34.8%达到ACR20(主要终点)。
- ACR50应答率分别为31.4%/32.1% vs 12.2%,ACR70为17.5%/17.3% vs 2.0%。
- IGA 0/1应答率分别为50.0%/57.3% vs 17.4%,PASI90为49.4%/45.5% vs 12.0%,MDA为18.8%/23.9% vs 5.4%(所有P<0.001)。
- 截至第24周,Guselkumab每4周组、每8周组和安慰剂组分别有46.7%、53.6%和48.3%的参与者发生至少一项不良事件。
- 发生一例死亡(心肌梗死)。
关键数值与推荐
- 主要终点:第24周ACR20应答率。
- 次要终点包括ACR50、ACR70、IGA 0或1分且改善≥2级、PASI90、MDA,均按意向治疗分析。
临床怎么用
- 对于一种TNF抑制剂应答不佳的活动性PsA患者,Guselkumab每4周或每8周方案均可考虑作为治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of guselkumab, an interleukin-23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor. METHODS: In SOLSTICE (phase 3b, randomized, multicenter, double-blind, placebo-controlled study), enrolled adults with active PsA (three or more swollen joints; three or more tender joints; C-reactive protein ≥ 0.3 mg/dL) and inadequate response to one prior TNF inhibitor were randomized to guselkumab 100 mg every 4 weeks (Q4W), guselkumab 100 mg at weeks 0 and 4 and then Q8W, or placebo with crossover to guselkumab Q4W at week 24. The primary endpoint was ≥20% improvement in American College of Rheumatology criteria (ACR20) at week 24. Secondary endpoints included ACR50, ACR70, Investigator's Global Assessment of psoriasis (IGA) score of 0 or 1 with ≥2-grade improvement, ≥90% improvement in Psoriasis Area and Severity Index (PASI90), and minimal disease activity (MDA) at week 24 and were analyzed by intention-to-treat. RESULTS: Analyses included 451 randomized participants (Q4W n = 150; Q8W n = 151; placebo n = 150). At week 24, significantly greater proportions of guselkumab (Q4W/Q8W)-treated participants versus placebo-treated participants, respectively, achieved ACR20 (primary endpoint: 58.6%/62.2% vs 34.8%), ACR50 (31.4%/32.1% vs 12.2%), ACR70 (17.5%/17.3% vs 2.0%), IGA 0/1 response (50.0%/57.3% vs 17.4%), PASI90 (49.4%/45.5% vs 12.0%), and MDA (18.8%/23.9% vs 5.4%) (all P < 0.001). Through week 24, 46.7%, 53.6%, and 48.3% of participants receiving guselkumab Q4W, guselkumab Q8W, and placebo, respectively, had one or more adverse event. One death occurred (myocardial infarction). CONCLUSION: Comparable efficacy was observed with both guselkumab regimens in participants with active PsA and inadequate response to one prior TNF inhibitor; safety findings were consistent with the known profile of guselkumab in patients with psoriatic disease.
引用
- Ogdie A, Merola JF, Mease PJ, et al. Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study. Arthritis Rheumatol. 2026. PMID: 41670439. doi:10.1002/art.70092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。